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INTRODUCTION
During terminal sickness, patients
present shared signs and symptoms ir-
respective of the primary insult being
an infection or an injury. Exogenous
bacterial toxins such as endotoxin
(lipopolysaccharide [LPS]), a cell wall
component in all gram-negative bacteria
that may cause inflammation and septic
shock, are cleared from circulation
within minutes after exposure, whereas
inflammation persists for many days (1).
This puzzling temporal dichotomy initi-
ated our original studies to elucidate
whether inflammation and death during
terminal sickness could be due to over-
production of endogenous endotoxin-
like molecules (2). If confirmed, it
would explain why patients look the
same regardless of the absence or pres-
ence of foreign invaders expressing
PAMPs (pathogen-associated molecular
pattern molecules). We unexpectedly
identified the endogenous nucleoprotein
high mobility group box protein 1
(HMGB1), present in all cells, as a mole-
cule released to the extracellular envi-
ronment, where it acts as a critical
proinflammatory mediator in endotox-
emia. Furthermore, HMGB1 even oper-
ates via the identical cellular receptor
complex (toll-like receptor 4 [TLR4]) as
LPS to generate inflammation (3). Sub-
sequent studies revealed that HMGB1
occupies a crucial functional global role
as a signaling molecule that informs
other cells that damage or invasion has
occurred. The principle established is
that products of cellular injury activate
fundamental defense mechanisms that
are indistinguishable from responses ac-
tivated by molecules from pathogens.
We here update research progress made
in the HMGB1 field during the past 15
years, with special emphasis on the role
of HMGB1 as a prototypic damage-
 associated molecular pattern (DAMP) in
inflammation.
HMGB1 AS AN ENDOGENOUS
ENDOTOXIN-LIKE MEDIATOR OF
INFECTION
The discovery of HMGB1 in 1999 as a
secreted protein highlighted the role of
extracellular HMGB1 in inflammation
and infection. In these studies,
macrophages were activated in vitro by
LPS, and the supernatants were screened
for macrophage-derived molecules,
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which resulted in the detection of extra-
cellular HMGB1 as a delayed mediator
after LPS stimulation. Systemic HMGB1
levels in vivo in mice started by 8 h and
increased substantially from 16 to 32 h
after LPS administration (2). HMGB1
thus appears remarkably late compared
with other proinflammatory molecules,
which are generally released within a
few hours after initiation of sepsis (Fig-
ure 1) (2). The delayed HMGB1 release
widens the temporal window of treat-
ment opportunity with HMGB1 antago-
nists for sepsis patients in a noticeably
unique way. This strategy has not yet
been tested in clinical trials, but has
proven highly successful in multiple pre-
clinical settings (reviewed in [4]). The
molecule is 99% identical in all mammals,
a fact that may underpin the predictive
clinical value of HMGB1 antagonist re-
sults observed in animal experiments. The
exposure of cultured human monocytes to
HMGB1 stimulated the release of multiple
proinflammatory cytokines including
tumor necrosis factor (TNF), interleukin
(IL)-1, IL-6, IL-8 and macrophage inflam-
matory protein (MIP)-1. The kinetic re-
sponses for HMGB1- and LPS-mediated
TNF release are distinctly different.
HMGB1-induced TNF release is biphasic
with a delayed second wave, whereas
LPS-mediated TNF release only occurs in
a monophasic early mode (5). The biologi-
cal role of extracellular HMGB1 has been
extensively studied in mice with gram-
negative bacteria sepsis induced by cecal
ligation and puncture (CLP) (reviewed in
[4]). Treatment with neutralizing mono-
clonal anti-HMGB1 antibodies amelio-
rates tissue injury and reduces lethality in
this sepsis model (6). Recent studies con-
firmed that siRNA-specific knockdown of
HMGB1 in macrophages and dendritic
cells suppressed HMGB1 release, reduced
the cytokine storm and rescued human-
ized mice from CLP sepsis- induced 
lethality (7).
Mice that survive their CLP sepsis de-
velop significant, persistent impairments
in learning and memory, and anatomic
changes in the hippocampus associated
with a loss of synaptic plasticity (8).
Serum HMGB1 levels are increased in
these animals at least 8 wks after initia-
tion of CLP. Administration of neutraliz-
ing anti-HMGB1 monoclonal antibodies
to survivors, on d 9–11 after onset of peri-
tonitis when no obvious signs or symp-
toms of ongoing inflammation occurred,
significantly improved memory impair-
ments and brain pathology. Administra-
tion of recombinant HMGB1 to naive
mice recapitulated the memory impair-
ments. This observation is interesting,
since up to 25% of patients surviving se-
vere sepsis are cognitively impaired. One
may speculate whether HMGB1-blocking
treatment might prevent this disabling
late complication in patients, too.
In addition to being engaged in bacter-
ial infections, HMGB1 and the closely re-
lated molecules HMGB2 and HMGB3 act
as universal sensors for cytosolic nucleic
acids during virus infections. Tian et al.
(9) first demonstrated that HMGB1 is 
involved in DNA- containing complex–
mediated immune responses via TLR9.
Later, Yanai et al. (10) confirmed that
HMGB1 binds to all immunogenic nu-
cleic acids examined and mediates im-
mune responses by stimulating the tran-
scription of type 1 interferons, IL-6 and
RANTES from immune cells or embry-
onic fibroblasts. Extracellular HMGB1
carrying nucleic acids binds to the recep-
tor for advanced glycation end products
(RAGE) and gets internalized via dy-
namin-dependent endocytosis (11),
which enables the transported nucleic
acids to interact with intracellular recep-
tors to mediate interferon and cytokine
responses. HMGB1-deficient cells mount
greatly diminished immune responses
when stimulated with viral DNA or
RNA compared with wild-type control
cells. Synchronized knockdown of all
three HMGB proteins inhibits the re-
sponse to viral nucleic acid stimulation
compared with solitary HMGB1 knock-
down, indicating that HMGB proteins
share antiviral functionality (10). Thus,
HMGB proteins play an essential role as
universal sentinels in nucleic acid–acti-
vated innate immune responses.
HMGB1 AS A MEDIATOR OF STERILE
INJURY
The understanding of DAMP came
from original work by Matzinger (12),
who in 1994 suggested that the innate
immune system detects and reacts to
“danger” via release of host-derived me-
diators, what we now call “DAMP mole-
cules.” This idea was brave, since the
prevailing dogma at that time predicted
that the function of the immune system
was to recognize non–self-molecules.
DAMPs are in general nuclear and cy-
tosolic endogenous proteins exerting
well-defined intracellular roles in the ab-
sence of cellular stress. When released
extracellularly after tissue damage or in-
jury, these molecules promote innate and
adaptive immune responses and do not
maintain their previous intracellular ac-
tivities. HMGB1 is one of the first identi-
fied members of the DAMP molecular
family. Bianchi and coworkers made the
seminal observation that necrotic cells
from HMGB1- deficient mice, in contrast
to wild-type mice, have a markedly de-
creased ability to induce TNF release
from cocultured macrophages. Apoptotic
Figure 1. Early versus late mediators of en-
dotoxin lethality. Vertebrates treated with
lethal doses of LPS succumb at latencies of
up to several days, long after serum TNF
and IL-1β have returned to basal levels. The
timing for HMGB1 release is delayed and
parallels the onset of lethality in endotox-
emia and sepsis. Reprinted with permission
of the American Thoracic Society. Copy-
right © 2015 American Thoracic Society.
Wang H, Yang H, Czura CJ, Sama AE, Tracey
KJ. (2001) HMGB1 as a late mediator of
lethal systemic inflammation. Am. J. Respir.
Crit. Care Med. 164(10 Pt 1):1768–73 (cited
as reference [49] in the current review).
S 8 |  Y A N G  E T  A L .  |  M O L  M E D  2 1  ( S U P P L E M E N T  1 ) ,  S 6 - S 1 2 ,  2 0 1 5
H M G B 1  A S  A  D A M P
cells from any source retains their nu-
clear HMGB1 strongly bound to the
chromatin located within cell mem-
brane–encircled cell fragments and do
not induce TNF production in
macrophage cocultures (13). Ombrellino
et al. (14) provided the original clinical
report of a case of sterile injury that gen-
erated increased HMGB1 serum levels.
In the absence of infection, hemorrhagic
shock stimulated a systemic release of
HMGB1. Intestinal epithelial cells were
recently identified as the main source for
the detrimental HMGB1 release in an ex-
perimental model of hemorrhagic-in-
duced systemic inflammation (15). Stroke
patients also express increased circulat-
ing HMGB1 levels within hours after the
ischemic tissue damage (16). Studies
from Billiar’s group confirmed that
HMGB1 may act as an early mediator of
inflammation and organ damage in he-
patic  ischemia/reperfusion injury (17).
Systemic HMGB1 levels were increased
during liver ischemia/reperfusion injury
as early as 1 h after reperfusion and then
increased in a time-dependent manner
up to 24 h. Inhibition of extracellular
HMGB1 activity with neutralizing anti-
body significantly decreased liver dam-
age after ischemia/reperfusion in mice,
whereas administration of recombinant
HMGB1 worsened the injury (17). In-
creased extracellular HMGB1 expression
has also been observed in several addi-
tional sterile injury models, including
collagen-induced arthritis or during the
spontaneous development of arthritis in
mice (18,19). Systemic administration of
anti-HMGB1 antibodies significantly
ameliorated these autoimmune diseases,
indicated by reduced weight loss and di-
minished cartilage/bone destruction in
arthritic joints (18). Taken together, these
studies establish extracellular HMGB1 as
a critical mediator of both sterile and in-
fectious inflammation.
REDOX REGULATION OF HMGB1
PROINFLAMMATORY ACTIVITIES
HMGB1 contains 215 amino acids (aa)
with two folded DNA binding motifs
called box A (aa 9–79) and box B (aa
95–163) and an acidic C tail (aa 186–215)
(20). HMGB1 has two nuclear localization
sequences (NLSs) located in box A (aa
28–44) and between box B and the C tail
(aa 179–185). Truncated mutants of
HMGB1 identified that HMGB1 box B
protein preserves the cytokine activity of
HMGB1 (21), whereas recombinant box A
protein acts as an antagonist of HMGB1
(22). HMGB1 receptor usage and subse-
quent biological activities depend on the
redox state of each of its three cysteines
(C23, C45 and C106; Figure 2). Fully re-
duced HMGB1, which expresses three
cysteine thiol residues, exerts chemotactic
activity by forming a hetero-complex with
CXCL12, which binds to the CXCL12-re-
ciprocal receptor CXCR4 and initiates
chemotaxis in a synergistic fashion com-
pared with CXCL12 alone. The cytokine-
stimulating activity of HMGB1 requires
C23 and C45 to form a disulfide link,
whereas C106 must express a thiol group
(23). This distinctive molecular conforma-
tion enables HMGB1 to bind and signal
via the TLR4/myeloid differentiation fac-
tor-2 (MD-2) complex to induce cytokine
release (3,23,24). The fully reduced form
of HMGB1 with or without CXCL12 can-
not activate the TLR4/MD-2 signaling
pathway, and the disulfide HMGB1 can-
not activate the CXCL12/CXCR4 path-
way (25). HMGB1 with any of the cys-
teine terminally oxidized (sulfonyl
HMGB1) has no identified immune-
 modulating activity (Figure 3). Together,
these studies reveal that posttranslational
modifications of HMGB1 determine its
role in inflammation and immunity.
EXTRACELLULAR HMGB1 RELEASE
HMGB1 release occurs during tissue
injury or microbial invasion via two
major pathways: one passive and the
other active. Passive release, which oc-
curs in the context of necrotic cell death,
is nearly instantaneous. Active HMGB1
secretion is a much slower process that
requires two essential steps: the initial
step is to translocate nuclear HMGB1 to
the cytoplasm, which depends on
JAK–STAT signaling that will generate
hyperacetylation of critical lysine
residues located in the two NLS sites
(26). This molecular modification of
HMGB1 prevents the continuous
 bidirectional shuttle of HMGB1 between
the cytoplasm and the nucleus and
leads to cytoplasmic accumulation of
hyperacetylated HMGB1. The second
step involves a gradual induction of
programmed, proinflammatory cell
death (pyroptosis) that allows cytoplas-
mic HMGB1 to reach the extracellular
space (27,28) or alternatively via exocy-
tosis of secretory lysosomes that deliver
Figure 2. Structure of HMGB1 and its functionality. HMGB1 has 215 amino acids, including
two DNA binding domains (box A and box B) and an acidic tail. Box A acts as an HMGB1
antagonist, whereas box B exerts the cytokine-inducing function of HMGB1. The minimal
sequence for the proinflammatory activity of box B resides at aa 89–109. HMGB1 has
three cysteines with two located at positions 23 and 45 in box A and one at position 106
in box B. HMGB1 contains two NLSs with one located in box A (aa 28–44) and another lo-
cated in the linker region between box B and the C tail (aa 179–185).
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HMGB1 outside cells (29). However, the
intracellular signal pathways that con-
trol the sequestration of cytoplasmic
HMGB1 in secretory lysosomes are not
fully revealed yet. Pyroptosis requires
the function of the intracellular enzyme
caspase-1 that is activated by the in-
flammasome system. Inflammasomes
are intracellular multiprotein complexes
that promote the secretion of the impor-
tant proinflammatory mediators IL-1β,
IL-18 and HMGB1. Genetic deletion of
both IL-1β and IL-18 did not confer any
protection against lethal endotoxemia,
although caspase-1 gene-deficient mice
were totally protected. Most transgenic
caspase-1 knockout mice also lack 
caspase-11 and consequently have a re-
duced capacity for induction of pyro-
ptosis. Remarkably enough, neutraliza-
tion via HMGB1-specific antibodies
significantly prevented endotoxemia-
 induced lethality (27). Inflammasome-
induced HMGB1 release leads to extra-
cellular, hyperacetylated HMGB1, which
is thus a novel biomarker for pyroptotic
cell death (28). In contrast, necrotic as
well as apoptotic cell deaths do not gen-
erate hyperacetylated HMGB1. The
redox state of HMGB1 released after py-
roptosis is generally in the disulfide
form, after necrosis in the fully reduced
or disulfide forms and after apoptosis in
the fully oxidized form (sulfonyl
HMGB1).
It was recently demonstrated that
HMGB1 release is controlled by a 
neurotransmitter-mediated signaling
pathway (30). Acetylcholine, from neu-
rons as well as lymphocytes, inhibits in-
flammasome activation via α7 nicotinic
acetylcholine receptors (α7 nAchR) pres-
ent on the mitochondrial surface.
Acetylcholine may penetrate the outer
cell membrane in the presence of extra-
cellular ATP. Mitochondrial α7 nAchR
stimulation stabilizes the surface mem-
brane of the organelles and attenuates
the release of mitochondrial nucleic
acids after stress-induced damage. The
inflammasome system can be readily ac-
tivated by intracellular DNA and RNA.
The acetylcholine-mediated reduction of
the cytoplasmic presence of mitochon-
drial nucleic acids thus prevents further
inflammasome activation. Genetic dele-
tion of α7 nAchR significantly enhances
inflammasome activation.
The accumulation of cytoplasmic
HMGB1 is important for additional key
cellular functions such as promoting 
mitophagy/autophagy, self-protective
processes that remove damaged mito-
chondria and clear intracellular micro-
bial intruders. Cytoplasmic HMGB1 has
the capacity to initiate these events by
binding to Beclin-1, required for the for-
mation of autophagosomes. Manipula-
tions to regulate intracellular HMGB1
traffic may on one hand diminish extra-
cellular HMGB1 release, but at the same
time interfere with autophagy capacity
with hazardous consequences for the
host (31). Future therapeutic strategies
to pacify excessive extracellular HMGB1
activity should consider the fact that
HMGB1 location is critical for HMGB1
functions.
HMGB1 RECEPTORS
HMGB1 signals via multiple seem-
ingly unrelated receptors, all previously
identified for their capacity to interact
with well-characterized exogenous or
endogenous ligands (9,10,25,32–42). To
date, at least 11 different HMGB1 recep-
tors have been described and are out-
lined in Table 1. Two of them (TLR4 and
RAGE) will be discussed here, since
there are important recent observations
that are helpful for a better understand-
ing of HMGB1 biology.
TLR4/MD-2 is a mandatory HMGB1
receptor complex for cytokine produc-
tion in macrophages and the interaction
requires the disulfide HMGB1 redox iso-
form, which binds the TLR4 coreceptor
MD-2 with nanomolar avidity, just like
LPS but at another MD-2 site (3,24).
Other redox isoforms of HMGB1 do 
not bind to MD-2 and hence do not 
activate the TLR4 system (Table 2) (3).
MD-2–deficient macrophages have a
markedly reduced HMGB1-mediated
nuclear factor (NF)-κB translocation and
TNF release. Taken together, these ob-
servations confirm the specificity of the
immune-stimulatory activities of
HMGB1. There have been concerns
Figure 3. Redox-dependent regulation of HMGB1 cytokine activity. Disulfide HMGB1 inter-
acts with MD-2 to facilitate the TLR4/MD-2 complex formation to elicit inflammatory re-
sponses. Fully reduced HMGB1 complexes with CXCL12 to induce recruitment of immune
cells and other cells meant for repair. Terminal oxidation of any cysteine residue (sulfonyl
HMGB1) prevents HMGB1 from expressing any cytokine or chemotactic activity.
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about the specificity of HMGB1 as a lig-
and for the TLR4 axis because of the
possible LPS contamination in prepara-
tions of recombinant HMGB1. However,
batches of disulfide HMGB1 subjected
to cysteine redox changes lose their abil-
ity to activate the TLR4/MD-2 receptor
complex. These findings prove the ca-
pacity of disulfide HMGB1-TLR4/MD-2
signaling without a need for cofactors.
RAGE is the first HMGB1 receptor that
was identified, discovered by Rauvala
and coworkers in 1999 as a ligand-recep-
tor interaction mediating neurite out-
growth in the fetal mouse brain, without
signs of concomitant inflammation (43).
The same group later identified the
RAGE binding site to be located in the
HMGB1 sequence 150–183. Further
RAGE-HMGB1 research work on conse-
quences of this signaling pathway per-
formed in many laboratories has focused
on cell migration, cell differentiation and
upregulation of other HMGB1 receptors
(reviewed in [44]). Two recently pub-
lished HMGB1-RAGE papers bring excit-
ing and essential information to the
HMGB1 field. Xu et al. (11) uncovered
that HMGB1 acting through RAGE bind-
ing and dynamin-dependent signaling
initiates HMGB1 endocytosis, which in
turn induces cell pyroptosis with release
of proinflammatory mediators from the
studied macrophages (11). They provide
evidence that these important cellular
events occur both in vitro and in vivo. As
stated above, TLR4 is necessary for
HMGB1-dependent cytokine production
in macrophages, but at the same time,
we and others have previously demon-
strated that a quantitatively optimal
HMGB1-mediated cytokine response also
requires RAGE (45–47). RAGE knockout
macrophages produce substantially
lower amounts of cytokines after TLR4
activation (45). It is conceivable that the
RAGE-mediated endocytosis of HMGB1,
equipped with or without partner mole-
cules, may provide the answer to explain
the elusive synergy mechanism occur-
ring when various proinflammatory mol-
ecules complexed to HMGB1 are pre-
sented to the immune system.
Intracellular DAMP and PAMP receptors
may thus be exposed to and activated by
mediators that would never reach them
without the helpful HMGB1 transport
and intracellular delivery. The HMGB1-
mediated pyroptosis may then enable the
proinflammatory molecules synthesized
in the endosomes and cytoplasm to be
released extracellularly. The second excit-
ing novel HMGB1-RAGE report by
LeBlanc et al. (48) describes an additional
RAGE-binding epitope in HMGB1 lo-
cated in the box A domain (binding re-
gion sequence 23–50) (48). This observa-
tion suggests the possibility that HMGB1
may mediate different biological func-
tions when interacting with RAGE de-
pending on which of the two RAGE-
binding epiotopes is involved. Cysteine
redox states in box A need to be sorted
out regarding requirements for RAGE in-
teraction, in analogy to the HMGB1-
TLR4/MD-2 story. Is the novel RAGE-
binding box A epitope important for
HMGB1/partner molecule synergy? It
has been known since 2002 that recombi-
Table 1. HMGB1 receptor families.
Receptors Complex with Effects References
TLR4/MD-2 — Cytokine release 3,16,39
RAGE — Cell migration, pyroptosis, internalization of HMGB1-partner molecules 11,32,37,45
CD24/siglet 10 — Antiinflammatory 31
Integrin/Mac1 — Cell recruitment 33
TIM3 — Reduce tumor immunity 34
TLR4/MD-2 LPS, NMDAR Synergistic cytokine release, increased neuroinflammation 35,38
TLR2 Pam3CSK4, nucleosomes Synergistic cytokine release, enhanced autoantibody formation 40,41
TLR3/7/9 Nucleic acids Synergistic cytokine release 9,10
IL-1R1 IL-1α/β Synergistic cytokine release 35,36
CXCR4 CXCL12 Synergistc chemotaxis 24
Extracellular HMGB1, either alone or in conjunction with other molecules, elicits diverse immune responses by activating multiple signaling
pathways.
Table 2. Isoforms of HMGB1 and MD-2 binding and cytokine/chemokine activity.
HMGB1 isoforms MD-2 binding Cytokine activity Chemokine activity
Disulfide + + –
Hg-modified – – –
Fully reduced – – +
H2S-modified – – –
Sulfonyl – – –
Isoforms of HMGB1, generated by a synthetic formation of mercury thiolate on C106 (Hg-
modified), by S-sulfhydration (H2S) to convert cysteine thiol (–SH) group to –SSH (H2S-modified),
by exposure to reducing agent dithiothreitol (fully reduced) or oxidized by hydrogen
peroxide (sulfonyl), were tested for their MD-2-binding via Biosensor-based surface plasmon
resonance analysis (BIAcore) (3). Only disulfide HMGB1 binds to MD-2 and induced TNF
secretion. Fully reduced HMGB1 has chemokine activity.
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nant box A peptide acts as a powerful
HMGB1 antagonist in many experimen-
tal models of various diseases (18) (re-
viewed in [4]). However, the effector
mechanism is not well understood. It has
been suggested that the truncated
HMGB1 box A protein may interfere
with the TLR4 binding of the box B epi-
tope recognizing MD-2, but the evidence
is not convincing. However, the identifi-
cation of the RAGE-binding box A epi-
tope raises the question of whether re-
combinant box A protein may work via
RAGE blockade, preventing critical full-
length HMGB1/RAGE interactions. Fu-
ture research work is needed to clarify
these unresolved HMGB1 issues, which
have important therapeutic implications.
P5779 AS AN MD-2 TARGETING
HMGB1-SPECIFIC ANTAGONIST
Screening of an HMGB1-derived pep-
tide library revealed that a tetramer
peptide (sequence FSSE, P5779) located
within the HMGB1 box B domain (aa
105–108) when C106 was replaced by a
serine residue, acts as a specific in-
hibitor of HMGB1. P5779 binds MD-2
and disrupts HMGB1-TLR4/MD-2 liga-
tion and subsequent cytokine induction
(Figure 4). While P5779 dose depend-
ently inhibits HMGB1-induced cytokine
release from macrophage cultures, it
does not alter LPS-TLR4 interaction or
other studied ligand-TLR collabora-
tions, supporting its role as a specific
HMGB1 antagonist. The molecule alle-
viates HMGB1-induced inflammation in
various preclinical models of HMGB1-
mediated diseases including CLP-
 induced sepsis. Administration of
P5779 ameliorated liver damage, in
sterile injury models induced by liver
ischemia/reperfusion or by acetamino-
phen overdose (3). The results may di-
rect strategies attenuating DAMP-
 mediated signaling while sparing
PAMP signaling through TLR4.
CONCLUSION
Since the discovery of HMGB1 as a
proinflammatory mediator 16 years
ago, the area of HMGB1 research has
grown exponentially. The number of
publications reporting advances in
HMGB1 biology has increased from 281
during the 5-year period of 1995–2000
to 2,261 reports during 2009–2014
(PubMed). The process of gaining a bet-
ter understanding of HMGB1 functions
has established that once released out-
side of the cells, HMGB1 acts as a pro-
totypic DAMP and a promiscuous dan-
ger sensor for the immune system and
other organs. This review has high-
lighted functions of HMGB1 in its vari-
ous forms from the whole molecule to
individual domains and critical amino
acid residues; its immunogenic activity
either alone or in complex with cofac-
tors; and the functional importance of
different redox states of cysteine
residues, to elucidate shifting patho-
physiological roles of HMGB1. The
worldwide accumulated information re-
garding HMGB1 biology suggests that
the time has come to translate the
pathophysiologically relevant results
from experimental models into thera-
peutics for clinical trials.
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